Related Experiment Videos
Heart and heart-lung transplantation Papworth Hospital 1979 to 1987
1Papworth Hospital, Cambridge, England.
Insights
Heart transplantation offers good quality of life post-surgery, with reduced hospital stays and costs. Heart-lung transplantation shows promise but requires further development for long-term success.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunosuppression Therapy
Background:
- Heart transplantation is an established therapy for end-stage heart disease.
- Heart-lung transplantation is in its developmental phase with acceptable short-term outcomes.
- Quality of life for transplant survivors is generally good after the initial recovery period.
Purpose of the Study:
- To assess the current status and future potential of heart and heart-lung transplantation.
- To identify challenges and areas for improvement in transplant services.
- To discuss management principles and therapeutic advancements in cardiac transplantation.
Main Methods:
- Review of clinical outcomes and management strategies for heart and heart-lung transplant recipients.
- Analysis of trends in hospital stay duration and transplantation costs.
- Discussion of immunosuppression protocols, specifically triple therapy and its impact on side effects.
Main Results:
- Significant reductions in hospital stay duration and cost per patient over the last three years.
- Established management principles for heart and heart-lung recipients.
- Anticipated improvements in medium-term results through management of cyclosporine (CsA)-induced nephrotoxicity and hypertension.
Conclusions:
- Heart transplantation is a viable and established treatment for life-threatening heart conditions.
- Heart-lung transplantation requires further research and development for long-term efficacy.
- Increasing demand for transplant services necessitates addressing funding and resource limitations, particularly in the UK.
Abstract:
The quality of life for those who survive the first 3 months after transplantation is generally good. The duration of hospital stay and the cost of transplantation per patient have been reduced during the last 3 years. Cardiologists are coming to appreciate the therapeutic potential of both heart and heart-lung transplantation and one of the chief logistic problems faced is that of increasing the provision of transplant services to match the increasing demand. Ultimately this will be donor-limited but at present in the United Kingdom the main limitation to the expansion of services is restriction of funding and resources. (The allocation for heart transplantation from the DHSS for the financial year 1987/88 is 4.3 million pounds). The broad principles of management of heart and heart-lung recipients have been established. Further improvement in medium-term results can be anticipated as a result of reducing CsA-induced nephrotoxicity and hypertension as a result of triple therapy and adjusting the components of that therapy to the individual needs of particular patients. Heart transplantation has now taken its place as an established therapy for life-threatening heart disease. Heart-lung transplantation is still going through its developmental phase with acceptable short-term results, but with much to learn in the mid- and long-term following transplantation.